Kato, Taro

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2 R ,6 R )-hydroxynorketamine

Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 188

Neurotrophic and Antidepressant Actions of Brain-Derived Neurotrophic Factor Require Vascular Endothelial Growth Factor

Deyama, S., Bang, E., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Biological Psychiatry

Treatment of Major DepressionNerve injury and regeneration

Cited by 116

GLYX-13 Produces Rapid Antidepressant Responses with Key Synaptic and Behavioral Effects Distinct from Ketamine

Liu, R.-J., Duman, C., Kato, T., Hare, B., Lopresto, D., Bang, E., Burgdorf, J., Moskal, J., Taylor, J., Aghajanian, G., et al. (2017) · Neuropsychopharmacology

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 105

Sestrin modulator NV-5138 produces rapid antidepressant effects via direct mTORC1 activation

Kato, T., Pothula, S., Liu, R.-J., Duman, C. H., Terwilliger, R., Vlasuk, G. P., Saiah, E., Hahm, S., & Duman, R. S. (2019) · Journal of Clinical Investigation

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 88

BDNF Release and Signaling Are Required for the Antidepressant Actions of GLYX-13

Kato, T., Fogaça, M. V., Deyama, S., Li, X.-Y., Fukumoto, K., & Duman, R. S. (2018) · Molecular Psychiatry

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 88